This site uses cookies, including third-party cookies, that help us to provide and improve our services. Read More

Cox 2 Inhibitors Market

Cox 2 Inhibitors Market

Cox 2 Inhibitors Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018-2026

Cox 2 Inhibitors  Market
FACT3221MR

Introduction

Cox 2 Inhibitors are a type of non-steroidal anti-inflammatory drugs. These drugs are responsible for decreasing the production of prostaglandins.

These drugs also reduce the production of chemicals that play an important role in promoting fever, inflammatory pain etc. Cyclooxygenase (Cox) is an enzyme, which is responsible for producing prostaglandins. The cyclooxygenase enzymes are of two types- cox 1 and cox 2. Cox 2 inhibitors, reduce the production of prostaglandins, hence, can reduce inflammatory pain, fever etc.

There are some of the safety issues, associated with cox 2 inhibitors, hence, they have been taken off from the U.S. market.

Also, many products have been recalled in the market. For example- Vioxx, which is a cox 2 inhibitor, was recalled worldwide in 2004 as it caused cardiovascular diseases such as heart attacks and heart strokes.

Bextra, which is another cox 2 inhibitor, was taken off from many European and U.S. markets in April 2005 due to cardiovascular risks and life-threatening skin reactions. There are many such other products like Prexige, which was withdrawn from most of the world’s market because of the severe liver damage caused by this drug. There are many controversies ongoing, which are criticizing the use of cox 2 inhibitors.

Celecoxib is the only COX-2 inhibitor, which is currently available in the United States. There is a new approach to manufacturing natural Cox 2 inhibitors, which is being adopted by the company, Sabinsa. Manufacture of natural Cox 2 inhibitors have very fewer side effects and is expected to be highly adopted by the people.

The high adoption rate of cox 2 inhibitors, such as aspirin pain killer, is one of the major factors, driving the growth of cox 2 inhibitors market. The increasing prevalence of chronic diseases, such as rheumatoid arthritis, osteoarthritis, and other diseases, is expected to increase the growth of cox 2 inhibitors market. Increasing awareness of physical activities can lead to sports injury, which can also be expected to drive the cox 2 inhibitors market.

The cox 2 inhibitors have many safety issues, hence, some of the cox 2 inhibitors have been withdrawn from the U.S. market. For example- Arcoxia is a cox 2 inhibitor, which is present in many countries but not in U.S. Dynastat is another cox 2 inhibitors, which is a form of injectable medicine and is not available in the U.S. market.

The safety issues, associated with cox 2 inhibitors, can restrain the growth of cox 2 inhibitors market. Intake of cox 2 inhibitors, can also cause gastrointestinal problems for the people, which decreases the demand of ox 2 inhibitors, hence, can hamper the growth of the overall market. Other side effects, such as headache, migraine, nausea, also decreases the demand for cox 2 inhibitors.

The report covers exhaustive analysis on:

  • Cox 2 Inhibitors Market Segments
  • Cox 2 Inhibitors Market Dynamics
  • Historical Actual Market Size, 2013 - 2015
  • Cox 2 Inhibitors Market Size & Forecast 2016 to 2024
  • Cox 2 Inhibitors Agents Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Cox 2 Inhibitors Market Drivers and Restraints

Know More Details About the Report

Regional analysis includes:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies for key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Avail customized purchase options for your needs

Segmentation

The global Cox 2 Inhibitors market is segmented on the basis of product type, Indication, distribution channel, and geography:

  • Segmentation by Product type
    • Selective Cox 2 Inhibitors
    • Non Selective Cox 2 Inhibitors
  • Segmentation by Indication
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Menstrual Cramps
    • Sports Injuries
    • Others
  • Segmentation by distribution channels
    • Hospital Pharmacies
    • Drug stores
    • Retail pharmacies

Based on the product type, the Cox 2 Inhibitors are segmented into selective cox 2 inhibitors and non- selective cox 2 inhibitors. Selective Cox 2 inhibitors are generally used for the treatment of osteoarthritis and rheumatoid arthritis.

Selective Cox 2 inhibitors are expected to hold the largest revenue share in Cox 2 Inhibitors market. Non Selective Cox 2 inhibitors include drugs such as aspirin, ibuprofen etc. Basically, Cox 2 inhibitors are used to treat inflammatory pain.

Based on the indication, the Cox 2 inhibitors market has been segmented into indication such as osteoarthritis, rheumatoid arthritis, menstrual cramps etc. Based on the end user, the market has been segmented into hospital pharmacies, drug stores, retail pharmacies. Drug stores are expected to show the maximum sales of Cox 2 inhibitors and can hold a large revenue share in the market.

Geographically, global Cox 2 Inhibitors market has been divided into few regions, such as North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. North America is expected to dominate the cox 2 inhibitors global market due to the presence of high research and developmental activities.

Europe is expected to hold the second largest share in the global Cox 2 Inhibitors market due to the presence of high population and high prevalence of rheumatoid arthritis. The Asia Pacific is expected to hold a large share in the cox 2 inhibitors market because of the presence of more number of people preferring inflammatory pan medicines.

There are only a few companies, such as Cadila Pharmaceuticals, which are manufacturing cox 2 inhibitors. Sabinsa manufactures natural herbal drugs and is focusing on manufacturing natural Cox 2 inhibitors.    

Need an Exclusive Report for your Unique Requirement?

Talk Show:

The Rise of Intelligent Packaging

Personalized, Connected and Sustainable

November 18, 2021 11:00-11:45 AM PST (USA & Canada)
This is a LIVE session
Future Market Insights MarketNgage Spring

- Our Clients -

Report Client

- Evaluate How Fact.MR's Report Can Help. -

Is the market research conducted by Fact.MR?

Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

What research methodology is followed by Fact.MR?

Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.

What are the sources of secondary research?

Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

Who are the respondents for primary research?

Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

Is a sample of this report available for evaluation?

Yes, you can request a sample, and it will be sent to you through an email.